X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
Provided By GlobeNewswire
Last update: Oct 24, 2024
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024.
Read more at globenewswire.comNASDAQ:XFOR (5/2/2025, 12:35:00 PM)
3.75
0 (0%)
Find more stocks in the Stock Screener
XFOR Latest News and Analysis
8 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
